Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening
- PMID: 22105249
- DOI: 10.1097/AOG.0b013e318238d030
Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening
Abstract
Objective: To estimate the effect of ultrasonographic screening on stage at detection and long-term disease-specific survival of women with epithelial ovarian cancer.
Methods: Eligibility included all asymptomatic women aged 50 years and older and women aged 25 years and older with a documented family history of ovarian cancer. From 1987 to 2011, 37,293 women received annual ultrasonographic screening. Women with abnormal screens underwent tumor morphology indexing, serum biomarker analysis, and surgery.
Results: Forty-seven invasive epithelial ovarian cancers and 15 epithelial ovarian tumors of low malignant potential were detected. No women with low malignant potential tumors experienced recurrent disease. Stage distribution for invasive epithelial cancers was: stage I, 22 (47%); stage II, 11 (23%); stage III, 14 (30%), and stage IV, 0 (0%). Follow-up varied from 2 months to 20.1 years (mean, 5.8 years). The 5-year survival rate for invasive epithelial ovarian cancers detected by screening was: stage I, 95%±4.8%; stage II, 77.1%±14.5%; and stage III, 76.2%±12.1%. The 5-year survival rate for all women with invasive epithelial ovarian cancer detected by screening as well as interval cancers was 74.8%±6.6% compared with 53.7%±2.3% for unscreened women with ovarian cancer from the same institution treated by the same surgical and chemotherapeutic protocols (P<.001).
Conclusion: Annual ultrasonographic screening of asymptomatic women achieved increased detection of early-stage ovarian cancer cases and an increase in 5-year disease-specific survival rate for women with ovarian cancer.
Level of evidence: II.
Comment in
-
Can ovarian cancer screening save lives? The question remains unanswered.Obstet Gynecol. 2011 Dec;118(6):1209-1211. doi: 10.1097/AOG.0b013e31823b49b3. Obstet Gynecol. 2011. PMID: 22105248 No abstract available.
Similar articles
-
Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening.Obstet Gynecol. 2018 Nov;132(5):1091-1100. doi: 10.1097/AOG.0000000000002921. Obstet Gynecol. 2018. PMID: 30303916 Free PMC article.
-
The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.Am J Obstet Gynecol. 2005 Apr;192(4):1214-21; discussion 1221-2. doi: 10.1016/j.ajog.2005.01.041. Am J Obstet Gynecol. 2005. PMID: 15846205
-
Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.J Clin Oncol. 2017 May 1;35(13):1411-1420. doi: 10.1200/JCO.2016.69.9330. Epub 2017 Feb 27. J Clin Oncol. 2017. PMID: 28240969 Free PMC article.
-
Feto-maternal outcomes of pregnancy complicated by epithelial ovarian cancer: a systematic review of literature.Eur J Obstet Gynecol Reprod Biol. 2015 Mar;186:97-105. doi: 10.1016/j.ejogrb.2015.01.010. Epub 2015 Jan 23. Eur J Obstet Gynecol Reprod Biol. 2015. PMID: 25668134 Review.
-
[Epithelial ovarian cancer - a change of paradigm].Ther Umsch. 2011 Oct;68(10):565-72. doi: 10.1024/0040-5930/a000215. Ther Umsch. 2011. PMID: 21968896 Review. German.
Cited by
-
High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.Biomedicines. 2024 Jan 19;12(1):229. doi: 10.3390/biomedicines12010229. Biomedicines. 2024. PMID: 38275400 Free PMC article. Review.
-
Serum Free Fatty Acid Changes Caused by High Expression of Stearoyl-CoA Desaturase 1 in Tumor Tissues Are Early Diagnostic Markers for Ovarian Cancer.Cancer Res Commun. 2023 Sep 13;3(9):1840-1852. doi: 10.1158/2767-9764.CRC-23-0138. Cancer Res Commun. 2023. PMID: 37712874 Free PMC article.
-
Advantages and Limitations of Ultrasound as a Screening Test for Ovarian Cancer.Diagnostics (Basel). 2023 Jun 15;13(12):2078. doi: 10.3390/diagnostics13122078. Diagnostics (Basel). 2023. PMID: 37370973 Free PMC article. Review.
-
Executive Summary of the Ovarian Cancer Evidence Review Conference.Obstet Gynecol. 2023 Jul 1;142(1):179-195. doi: 10.1097/AOG.0000000000005211. Epub 2023 Jun 7. Obstet Gynecol. 2023. PMID: 37348094 Free PMC article.
-
Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDO.Gynecol Oncol Rep. 2023 Mar 2;46:101157. doi: 10.1016/j.gore.2023.101157. eCollection 2023 Apr. Gynecol Oncol Rep. 2023. PMID: 36938343 Free PMC article.
References
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. 2010. CA Cancer J Clin 2011;61:133–4.
-
- Goff BA, Mandel LS, Melancen CH, Munz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;291:2705–12.
-
- Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al.. Development of an ovarian cancer symptom index. Cancer 2007;109:221–7.
-
- Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61:183–203.
-
- van Nagell JR, Higgins RV, Donaldson ES, Gallion HH, Powell DE, Pavlik EJ, et al.. Transvaginal sonography as a screening method for ovarian cancer. A report of the first 1000 cases screened. Cancer 1990;65:573–7.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
